About DNA-3-methyladenine glycosylase
DNA-3-methyladenine glycosylase (MPG) is a protein
from Homo sapiens identified by UniProt accession
P29372, 298 residues long.
MolForge cross-references it against 0 known binders and
121 disease associations.
Target properties
| Protein name | DNA-3-methyladenine glycosylase |
|---|
| UniProt accession | P29372 |
|---|
| Gene | MPG |
|---|
| Organism | Homo sapiens |
|---|
| Length | 298 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Approved drugs hitting this target (2)
DrugCentral-linked approved drugs that act on this protein.
Disease associations (121)
Diseases linked to this target (Open Targets).
- breast adenocarcinoma · score 0.18
- glioblastoma multiforme · score 0.14
- blood protein measurement · score 0.14
- central nervous system cancer · score 0.13
- adolescent idiopathic scoliosis · score 0.11
- hemoglobin measurement · score 0.11
- mean corpuscular volume · score 0.10
- mean corpuscular hemoglobin · score 0.08
- glioblastoma · score 0.08
- mean corpuscular hemoglobin concentration · score 0.08
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-P29372-F1 | alphafold | PREDICTED | 81.67 | — |
Amino-acid sequence (298 residues)
MVTPALQMKK PKQFCRRMGQ KKQRPARAGQ PHSSSDAAQA PAEQPHSSSD AAQAPCPRER CLGPPTTPGP YRSIYFSSPK GHLTRLGLEF FDQPAVPLAR AFLGQVLVRR LPNGTELRGR IVETEAYLGP EDEAAHSRGG RQTPRNRGMF MKPGTLYVYI IYGMYFCMNI SSQGDGACVL LRALEPLEGL ETMRQLRSTL RKGTASRVLK DRELCSGPSK LCQALAINKS FDQRDLAQDE AVWLERGPLE PSEPAVVAAA RVGVGHAGEW ARKPLRFYVR GSPWVSVVDR VAEQDTQA
Explore DNA-3-methyladenine glycosylase with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets